These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 22449381)

  • 1. Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats.
    Takuma K; Tanaka T; Takahashi T; Hiramatsu N; Ota Y; Ago Y; Matsuda T
    Eur J Pharmacol; 2012 May; 683(1-3):166-73. PubMed ID: 22449381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression.
    Padovan-Neto FE; Ferreira NR; de Oliveira-Tavares D; de Aguiar D; da Silva CA; Raisman-Vozari R; Del Bel E
    Neurosci Lett; 2013 Apr; 541():126-31. PubMed ID: 23428503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
    Padovan-Neto FE; Cavalcanti-Kiwiatkoviski R; Carolino RO; Anselmo-Franci J; Del Bel E
    Neuropharmacology; 2015 Feb; 89():87-99. PubMed ID: 25196732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
    Padovan-Neto FE; Echeverry MB; Tumas V; Del-Bel EA
    Neuroscience; 2009 Mar; 159(3):927-35. PubMed ID: 19302833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?
    Bortolanza M; Padovan-Neto FE; Cavalcanti-Kiwiatkoski R; Dos Santos-Pereira M; Mitkovski M; Raisman-Vozari R; Del-Bel E
    Philos Trans R Soc Lond B Biol Sci; 2015 Jul; 370(1672):. PubMed ID: 26009769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.
    Bortolanza M; Cavalcanti-Kiwiatkoski R; Padovan-Neto FE; da-Silva CA; Mitkovski M; Raisman-Vozari R; Del-Bel E
    Neurobiol Dis; 2015 Jan; 73():377-87. PubMed ID: 25447229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
    Azkona G; Sagarduy A; Aristieta A; Vazquez N; Zubillaga V; Ruíz-Ortega JA; Pérez-Navarro E; Ugedo L; Sánchez-Pernaute R
    Neuropharmacology; 2014 Apr; 79():726-37. PubMed ID: 24333147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.
    Lebel M; Chagniel L; Bureau G; Cyr M
    Neurobiol Dis; 2010 Apr; 38(1):59-67. PubMed ID: 20060905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
    Ruiz-DeDiego I; Mellstrom B; Vallejo M; Naranjo JR; Moratalla R
    Biol Psychiatry; 2015 Jan; 77(2):95-105. PubMed ID: 24857398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrastriatal injection of ionomycin profoundly changes motor response to l-DOPA and its underlying molecular mechanisms.
    Han C; Nie S; Chen G; Ma K; Xiong N; Zhang Z; Xu Y; Wang T; Papa SM; Cao X
    Neuroscience; 2017 Jan; 340():23-33. PubMed ID: 27771532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
    Valastro B; Dekundy A; Danysz W; Quack G
    Behav Brain Res; 2009 Jan; 197(1):90-6. PubMed ID: 18762218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The preferential nNOS inhibitor 7-nitroindazole and the non-selective one N(G)-nitro-L-arginine methyl ester administered alone or jointly with L-DOPA differentially affect motor behavior and monoamine metabolism in sham-operated and 6-OHDA-lesioned rats.
    Czarnecka A; Konieczny J; Lenda T; Lorenc-Koci E
    Brain Res; 2015 Nov; 1625():218-37. PubMed ID: 26319690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
    Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
    Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
    Meadows SM; Conti MM; Gross L; Chambers NE; Avnor Y; Ostock CY; Lanza K; Bishop C
    Mov Disord; 2018 Nov; 33(11):1740-1749. PubMed ID: 30485908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
    Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.